A fourth dose of bivalent or monovalent BA.1-adapted BNT162b2 vaccines was safe and elicited robust neutralizing responses in adults aged 18 to 55 years.
The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical ...
Dr. Raza Bokhari, Executive Chairman & CEO will participate in panel discussions and highlight Company's AI-enabled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results